<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04379362</url>
  </required_header>
  <id_info>
    <org_study_id>NL63647.091.17</org_study_id>
    <nct_id>NCT04379362</nct_id>
  </id_info>
  <brief_title>MRI-guided Focal Laser Ablation</brief_title>
  <acronym>Unicorn</acronym>
  <official_title>Magnetic Resonance Imaging-guided Focal Laser Ablation of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biolitec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soteria Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Siemens Corporation, Corporate Technology</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnetic resonance imaging-guided focal laser ablation of prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-center, interventional treatment, non-randomized, open label, single arm, phase II study with a medical device.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine incontinence incontinence</measure>
    <time_frame>At inclusion, 3 months, 6 months, 12 months and 24 months follow up.</time_frame>
    <description>To evaluate a change in the functional outcome urine incontinence before and after FLA in patients with localized low to intermediate risk prostate cancer (Gleason 3+3, 3+4 or Gleason 4+3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local cancer control</measure>
    <time_frame>At inclusion , 3 months, 6 months, 12 months and 24 months follow up.</time_frame>
    <description>To assess the safety outcome local cancer control achieved at the ablation site after FLA by multiparametric MR imaging and targeted prostate biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>At inclusion, 3 months, 6 months, 12 months and 24 months follow up.</time_frame>
    <description>To evaluate other functional outcomes (sexual, hormonal and bowel functions) before and after FLA in men with prostate cancer by using validated questionnaires e.g. International Prostate Symptom Score (IPSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Health Inventory for Men- International Index of Erectile Function (SHIM-IIEF)</measure>
    <time_frame>At inclusion, 3 months, 6 months, 12 months and 24 months follow up.</time_frame>
    <description>To evaluate other functional outcomes (sexual, hormonal and bowel functions) before and after FLA in men with prostate cancer by using validated questionnaires e.g. Sexual Health Inventory for Men- International Index of Erectile Function (SHIM-IIEF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Consultation on Incontinence Questionnaire (ICIQ)</measure>
    <time_frame>At inclusion, 3 months, 6 months, 12 months and 24 months follow up.</time_frame>
    <description>To evaluate other functional outcomes (sexual, hormonal and bowel functions) before and after FLA in men with prostate cancer by using validated questionnaires e.g. the International Consultation on Incontinence Questionnaire (ICIQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using a validated quality of life questionnaire (EORTC QLQ PR25</measure>
    <time_frame>At inclusion , 3 months, 6 months, 12 months and 24 months follow up.</time_frame>
    <description>To evaluate quality of life before and after FLA in men with prostate cancer by using a validated quality of life questionnaire (EORTC QLQ PR25).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>At inclusion , 3 months, 6 months, 12 months and 24 months follow up.</time_frame>
    <description>To evaluate the complication rate related to the technique</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Low or intermediate grade prostate cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Focal laser ablation</intervention_name>
    <description>Focal laser ablation</description>
    <arm_group_label>Low or intermediate grade prostate cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  MRI visible index lesion (on T2-weighted MR imaging or diffusion weighted imaging);

          -  Maximum MRI visible lesion size is ≤ 15 mm large axis;

          -  Life expectancy at inclusion of more 10 years;

          -  Diagnosis of prostate cancer confirmed by targeted biopsy using TRUS-MRI fusion or
             in-bore MRI guided biopsies;

          -  Criteria of low and intermediate risk of progression and eligibility for focal therapy
             (clinical stage of maximum T2c, maximum biopsy Gleason score of 4 + 3 on targeted
             biopsies, serum prostate specific antigen &lt; 15 ng/ml);

          -  Patient accepting to be included in an active surveillance protocol at the end of the
             study, in accordance with the recommendations of good practice.

        Exclusion criteria:

          -  History of prostate surgery;

          -  History of radiation therapy or pelvic trauma; history of proved acute or chronic
             prostatitis;

          -  History of tumor in the preceding 5 years (excluded: non-metastatic basal cell skin
             cancer);

          -  Severe urinary symptoms associated with benign hyperplasia of the prostate, and
             defined by an IPSS score &gt; 18;

          -  Tumor with MRI signs of extra-capsular extension or invasion of the seminal vesicles;

          -  Tumor with cribriform morphology;

          -  Maximum cancer core length &gt;3 mm and/or maximum Gleason score of 3+4 on systematic
             biopsies outside the visible tumor area on mpMRI;

          -  Impossibility to obtain a valid informed consent;

          -  Patients unable to undergo MR imaging, including those with contra-indications;

          -  Contra-indications to MR guided focal laser therapy (colitis ulcerosa, rectal
             pathology or abdomino perineal resection);

          -  Metallic hip implant or any other metallic implant or device that distorts local
             magnetic field and compromises the quality of MR imaging;

          -  Patients with evidence for nodal or metastatic disease;

          -  Patients with an estimated Glomerular Filtration Ratio (eGFR) &lt; 40 mL/min/1.73 m2.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Gender identity</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jurgen Fütterer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboudumc Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michiel Sedelaar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboudumc Nijmegen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annemarijke van Luijtelaar, MD</last_name>
    <phone>+31 (0)24 365 22 79</phone>
    <email>Annemarijke.vanLuijtelaar@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joyce Bomers, PhD</last_name>
    <phone>+31 (0)24 365 22 79</phone>
    <email>Joyce.Bomers@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annemarijke van Luijtelaar, MD</last_name>
      <phone>+31 (0)24 365 22 79</phone>
      <email>Annemarijke.vanLuijtelaar@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Joyce Bomers, PhD</last_name>
      <phone>+31 (0)24 365 22 79</phone>
      <email>Joyce.Bomers@radboudumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Jurgen Fütterer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michiel Sedelaar, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Focal laser ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The investigators will be author of submitted manuscripts in case they fulfill criteria for authorship according to regulations of scientific journals. After scientific publication of the results the study protocol, relevant data and findings will be made publically available for other centers to implement (parts) of this research into their standard clinical practice if they wish to do so.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

